dalteparin has been researched along with Acute Coronary Syndrome in 98 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized prospective clinical trial aimed to evaluate safety and efficacy of preoperative use of eptifibatide in high risk patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), requiring urgent coronary artery bypass graft surgery (CABG)." | 9.22 | Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial. ( Bochenek, A; Buldak, Ł; Buszman, P; Kondys, M; Milewski, K; Sanak, M; Wilczynski, M; Wita, K; Wybraniec, MT, 2016) |
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 9.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines gave fondaparinux a class I recommendation for use in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) undergoing invasive or conservative strategy." | 9.15 | Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes. ( Chi, YP; Li, WZ; Liu, C; Liu, R; Song, L; Wang, SP; Yan, HB; Zhao, HJ; Zheng, B; Zhou, P, 2011) |
| "This study sought to evaluate the relative safety and efficacy of fondaparinux and enoxaparin in patients with acute coronary syndromes (ACS) treated with glycoprotein (GP) IIb/IIIa inhibitors or thienopyridines." | 9.14 | Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) tria ( Afzal, R; Boden, WE; Budaj, A; Chrolavicius, S; Faxon, DP; Fox, KA; Granger, CB; Jolly, SS; Joyner, CD; Mehta, SR; Steg, PG; Valentin, V; Widimsky, P; Yusuf, S, 2009) |
| "The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%." | 9.14 | Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Flather, M; Fox, KA; Franzosi, MG; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Yusuf, S, 2009) |
| " We evaluated the immediate and early outcomes in patients with high-risk non-ST elevation acute coronary syndrome (NSTE ACS) who received tirofiban with conventional therapy compared to patients who received only conventional therapy (a combination of aspirin, clopidogrel, low-molecular-weight heparin with or without beta-blockers and angiotensin-converting enzyme inhibitors)." | 9.14 | Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective. ( Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN, 2010) |
| "Fondaparinux is a more cost-effective antithrombotic agent than enoxaparin in non-ST-elevation acute coronary syndrome." | 9.14 | Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. ( Bakhai, A; Flather, M; Lozano-Ortega, G; Mehta, SR; Ormanidhi, O; Palmer, S; Sambrook, J; Sculpher, MJ; Steg, PG; Weintraub, W, 2009) |
| "The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively." | 9.13 | Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008) |
| "In the ACUITY trial, 13,819 patients with moderate- or high-risk acute coronary syndromes (ACS) were randomized to heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition (GPI), bivalirudin plus GPI, or bivalirudin monotherapy." | 9.13 | Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Attubato, MJ; Ebrahimi, R; Feit, F; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Stone, GW, 2008) |
| "This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)." | 9.13 | Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Tria ( Bertrand, ME; Colombo, A; Cox, DA; Lansky, AJ; Lincoff, AM; Manoukian, SV; McLaurin, BT; Mehran, R; Moses, JW; Ohman, EM; Pocock, SJ; Stone, GW; Ware, JA; White, HD, 2008) |
| "Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS)." | 8.95 | Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis. ( Bundhun, PK; Shaik, M; Yuan, J, 2017) |
| "Fondaparinux is thought to have the most favorable risk-benefit profile among all anticoagulants in non-ST-elevation acute coronary syndrome (NSTE-ACS)." | 8.02 | Fondaparinux versus enoxaparin in the contemporary management of non-ST-elevation acute coronary syndromes. Insights from a multicenter registry. ( Almendro-Delia, M; Arboleda Sánchez, JA; Blanco-Ponce, E; Carmona-Carmona, J; Castillo Caballero, JA; Fernández García, I; García-Del Río, M; García-Rubira, JC; Hidalgo-Urbano, RJ; Izquierdo-Bajo, Á; Madrona-Jiménez, L; Rodríguez Yáñez, JC; Seoane-García, T; Soto Blanco, JM, 2021) |
| "There are limited data on bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) with positive biomarkers of myocardial necrosis (troponin and/or creatine kinase-myocardial band isoenzyme)." | 7.96 | Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triag ( Bansilal, S; Ben-Yehuda, O; Brener, SJ; Chen, S; Dangas, GD; Feite, F; Huang, X; Kirtane, AJ; Mehran, R; Redfors, B; Souza, CF; Stone, GW; Zhang, Y, 2020) |
| "Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction." | 7.83 | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. ( Bossa, AS; César, MC; Leal, TC; Okada, MY; Oliveira, MT; Pedroti, FC; Roque, EA; Silva, PG; Simões, SA; Soeiro, AM, 2016) |
| "Between 2006 and 2007, the use of fondaparinux in patients with acute coronary syndromes increased considerably, either because it was used instead of enoxaparin or because of a switch from UFH." | 7.76 | Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. ( Bassand, JP; Chopard, R; Descotes-Genon, V; Dutheil, J; Ecarnot, F; Meneveau, N; Schiele, F; Seronde, MF, 2010) |
| "The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding." | 7.74 | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. ( Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY, 2008) |
| "The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up." | 7.30 | Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023) |
| " The primary efficacy endpoint is a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, re-revascularization or stroke, and major bleeding events." | 7.11 | Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE. ( Fang, Z; Hu, X; Liu, Q; Tang, L; Xiao, Y; Zhou, S, 2022) |
| "Fondaparinux was compared with enoxaparin or usual care, depending on the setting." | 6.44 | Efficacy and safety of fondaparinux in patients with acute coronary syndromes. ( Bassand, JP; Cadroy, Y; Richard-Lordereau, I, 2007) |
| "Fondaparinux was introduced and evaluated in a number of large randomised, controlled trials." | 5.42 | Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand. ( Chaiyakunapruk, N; Nathisuwan, S; Permsuwan, U; Sukonthasarn, A, 2015) |
| "Fondaparinux has demonstrated equivalence to enoxaparin in reducing cardiovascular events, but with a lower rate of bleeding in patients using fondaparinux." | 5.38 | Cost-effectiveness of fondaparinux in patients with acute coronary syndrome without ST-segment elevation. ( Machado, M; Olimpio, A; Pepe, C; Ramos, R, 2012) |
| "Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH." | 5.36 | Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. ( Schiele, F, 2010) |
| "In patients with NSTE-ACS undergoing an early invasive strategy, treatment with bivalirudin alone significantly reduced major bleeding and improved net clinical outcomes during the upstream medical management phase with comparable rates of MACE." | 5.22 | Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial. ( Bernstein, D; Bertrand, ME; Cequier, AR; Deliargyris, EN; Desmet, W; Droppa, M; Gawaz, M; Geisler, T; Hoekstra, JW; Lincoff, AM; Mehran, R; Rasmussen, LH; Steinhubl, SR; Stone, GW, 2016) |
| "This randomized prospective clinical trial aimed to evaluate safety and efficacy of preoperative use of eptifibatide in high risk patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), requiring urgent coronary artery bypass graft surgery (CABG)." | 5.22 | Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial. ( Bochenek, A; Buldak, Ł; Buszman, P; Kondys, M; Milewski, K; Sanak, M; Wilczynski, M; Wita, K; Wybraniec, MT, 2016) |
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 5.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines gave fondaparinux a class I recommendation for use in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) undergoing invasive or conservative strategy." | 5.15 | Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes. ( Chi, YP; Li, WZ; Liu, C; Liu, R; Song, L; Wang, SP; Yan, HB; Zhao, HJ; Zheng, B; Zhou, P, 2011) |
| "The objective was to assess the safety and efficacy of bivalirudin monotherapy in patients with high-risk acute coronary syndrome (ACS) presenting to the emergency department (ED)." | 5.14 | Safety and efficacy of bivalirudin in high-risk patients admitted through the emergency department. ( Blomkalns, AL; Brogan, GX; Diercks, DB; Gersh, BJ; Hoekstra, JW; Hollander, JE; Manoukian, SV; Miller, CD; Peacock, WF; Pollack, CV; Stone, GW, 2009) |
| "In the OASIS-5 trial, fondaparinux reduced major bleeding with similar short-term efficacy as enoxaparin but lowered death and stroke during long-term follow-up." | 5.14 | Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. ( Afzal, R; Anderson, JA; Budaj, A; Eikelboom, JW; Fox, KA; Hirsh, J; Johnston, M; Mehta, SR; Yusuf, S, 2010) |
| " We evaluated the immediate and early outcomes in patients with high-risk non-ST elevation acute coronary syndrome (NSTE ACS) who received tirofiban with conventional therapy compared to patients who received only conventional therapy (a combination of aspirin, clopidogrel, low-molecular-weight heparin with or without beta-blockers and angiotensin-converting enzyme inhibitors)." | 5.14 | Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective. ( Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN, 2010) |
| " We examined the incidence and outcomes after bleeding in 20 078 patients with acute coronary syndromes (ACS) enrolled in the OASIS-5 trial who were treated with fondaparinux or the low-molecular weight heparin, enoxaparin." | 5.14 | Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Fox, KA; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2009) |
| "The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%." | 5.14 | Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Flather, M; Fox, KA; Franzosi, MG; Granger, CB; Joyner, CD; Mehta, SR; Peters, RJ; Yusuf, S, 2009) |
| " Patients age > or =75 years treated with bivalirudin alone had similar ischemic outcomes, but significantly lower rates of bleeding compared with those treated with heparin and glycoprotein IIb/IIIa inhibitors overall and in the PCI subset." | 5.14 | Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Alexander, KP; Bertrand, ME; Feit, F; Gersh, BJ; Hoekstra, J; Lopes, RD; Manoukian, SV; Ohman, EM; Pollack, CV; Stone, GW; White, HD, 2009) |
| "Fondaparinux is a more cost-effective antithrombotic agent than enoxaparin in non-ST-elevation acute coronary syndrome." | 5.14 | Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. ( Bakhai, A; Flather, M; Lozano-Ortega, G; Mehta, SR; Ormanidhi, O; Palmer, S; Sambrook, J; Sculpher, MJ; Steg, PG; Weintraub, W, 2009) |
| "The study is a prospective single centre open-label trial of patients with high-risk acute coronary syndrome treated with percutaneous intervention (PCI) who were randomized to anticoagulation with UFH or enoxaparin with HD-tirofiban (25 microg kg(-1) bolus)." | 5.14 | High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention. ( Aroney, CN; Bett, JH; Perrin, EJ; Ray, MJ; Walters, DL; Wood, P, 2010) |
| "This study sought to evaluate the relative safety and efficacy of fondaparinux and enoxaparin in patients with acute coronary syndromes (ACS) treated with glycoprotein (GP) IIb/IIIa inhibitors or thienopyridines." | 5.14 | Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) tria ( Afzal, R; Boden, WE; Budaj, A; Chrolavicius, S; Faxon, DP; Fox, KA; Granger, CB; Jolly, SS; Joyner, CD; Mehta, SR; Steg, PG; Valentin, V; Widimsky, P; Yusuf, S, 2009) |
| "The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively." | 5.13 | Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass ( Afzal, R; Avezum, A; Bassand, JP; Boden, WE; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Flather, M; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Piegas, LS; Rupprecht, HJ; Steg, PG; Widimsky, P; Yusuf, S, 2008) |
| "This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)." | 5.13 | Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Tria ( Bertrand, ME; Colombo, A; Cox, DA; Lansky, AJ; Lincoff, AM; Manoukian, SV; McLaurin, BT; Mehran, R; Moses, JW; Ohman, EM; Pocock, SJ; Stone, GW; Ware, JA; White, HD, 2008) |
| "In the ACUITY trial, 13,819 patients with moderate- or high-risk acute coronary syndromes (ACS) were randomized to heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition (GPI), bivalirudin plus GPI, or bivalirudin monotherapy." | 5.13 | Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Attubato, MJ; Ebrahimi, R; Feit, F; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Stone, GW, 2008) |
| "Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS)." | 4.95 | Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis. ( Bundhun, PK; Shaik, M; Yuan, J, 2017) |
| "These analyses suggest a more protective effect of well-controlled warfarin, but not enoxaparin, compared with dabigatran in preventing myocardial infarction in multiple clinical settings." | 4.89 | Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. ( Clemens, A; Fraessdorf, M; Friedman, J, 2013) |
| " Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy." | 4.86 | Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. ( Aïssaoui, N; Danchin, N, 2010) |
| " We explore the role of glycoprotein IIb-IIIa inhibitors and the direct thrombin inhibitor bivalirudin in ACS patients, and consider the difficulties involved in reducing ischemic events while limiting bleeding risks." | 4.84 | Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. ( Kwa, AT; Rogers, JH, 2008) |
| "Fondaparinux is thought to have the most favorable risk-benefit profile among all anticoagulants in non-ST-elevation acute coronary syndrome (NSTE-ACS)." | 4.02 | Fondaparinux versus enoxaparin in the contemporary management of non-ST-elevation acute coronary syndromes. Insights from a multicenter registry. ( Almendro-Delia, M; Arboleda Sánchez, JA; Blanco-Ponce, E; Carmona-Carmona, J; Castillo Caballero, JA; Fernández García, I; García-Del Río, M; García-Rubira, JC; Hidalgo-Urbano, RJ; Izquierdo-Bajo, Á; Madrona-Jiménez, L; Rodríguez Yáñez, JC; Seoane-García, T; Soto Blanco, JM, 2021) |
| "There are limited data on bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) with positive biomarkers of myocardial necrosis (troponin and/or creatine kinase-myocardial band isoenzyme)." | 3.96 | Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triag ( Bansilal, S; Ben-Yehuda, O; Brener, SJ; Chen, S; Dangas, GD; Feite, F; Huang, X; Kirtane, AJ; Mehran, R; Redfors, B; Souza, CF; Stone, GW; Zhang, Y, 2020) |
| "Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction." | 3.83 | Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. ( Bossa, AS; César, MC; Leal, TC; Okada, MY; Oliveira, MT; Pedroti, FC; Roque, EA; Silva, PG; Simões, SA; Soeiro, AM, 2016) |
| "Between 2006 and 2007, the use of fondaparinux in patients with acute coronary syndromes increased considerably, either because it was used instead of enoxaparin or because of a switch from UFH." | 3.76 | Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. ( Bassand, JP; Chopard, R; Descotes-Genon, V; Dutheil, J; Ecarnot, F; Meneveau, N; Schiele, F; Seronde, MF, 2010) |
| "The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding." | 3.74 | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. ( Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY, 2008) |
| "The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up." | 3.30 | Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023) |
| " The primary efficacy endpoint is a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction, re-revascularization or stroke, and major bleeding events." | 3.11 | Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE. ( Fang, Z; Hu, X; Liu, Q; Tang, L; Xiao, Y; Zhou, S, 2022) |
| " Strategies to ensure adherence to dosing guidelines of enoxaparin during PCI should be considered." | 2.75 | Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. ( Antman, EM; Aylward, PE; Califf, RM; Cohen, M; Kleiman, NS; Lan, L; Levine, GN; Mahaffey, KW; Pieper, KS; White, HD, 2010) |
| "We evaluated the early pharmacodynamic profile of the combined 30 mg intravenous and 1 mg/kg subcutaneous enoxaparin loading utilized in the TIMI 11B and ExTRACT TIMI 25 trials." | 2.74 | The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study). ( Atherley, TH; Fry, ET; Martin, JL; Martin, SS; Martin, T; Slepian, MJ, 2009) |
| "The administration of stack-on UFH to subjects already receiving recommended enoxaparin dosing may result in over-anticoagulation, and should be avoided." | 2.74 | Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. ( Bal dit Sollier, C; Drouet, L; Martin, J, 2009) |
| "Bleeding is associated with adverse outcome in acute coronary syndromes." | 2.73 | Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial. ( DeYoung, P; Fitchett, DH; Goodman, SG; Huynh, T; Langer, A; Weeks, A; Yan, AT; Yan, RT, 2008) |
| "Thrombocytopenia was defined as a platelet count <100 x 10(9)/L or a >50% decrease from baseline." | 2.73 | Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. ( Antman, EM; Bradner, JE; Gibson, CM; Giugliano, RP; Jang, IK; Morrow, DA; Qin, J; Scirica, B; Shui, A; Wiviott, SD; Yeh, RW, 2007) |
| " Dosing schedules based on pharmacodynamic and clinical data offer a seamless transition for enoxaparin from the medical management phase to PCI." | 2.47 | Use of low-molecular-weight heparins during percutaneous coronary intervention. ( Martin, JL; Slepian, M, 2011) |
| "Fondaparinux was compared with enoxaparin or usual care, depending on the setting." | 2.44 | Efficacy and safety of fondaparinux in patients with acute coronary syndromes. ( Bassand, JP; Cadroy, Y; Richard-Lordereau, I, 2007) |
| "Fondaparinux has been shown to be as effective as enoxaparin in the prevention of thrombosis in patients undergoing orthopedic surgery and showed similar results compared to enoxaparin or UFH in patients with deep-vein-thrombosis or pulmonary embolism." | 2.44 | Factor Xa inactivation in acute coronary syndrome. ( Barantke, M; Bonnemeier, H, 2008) |
| "Fondaparinux was introduced and evaluated in a number of large randomised, controlled trials." | 1.42 | Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand. ( Chaiyakunapruk, N; Nathisuwan, S; Permsuwan, U; Sukonthasarn, A, 2015) |
| " In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization." | 1.39 | Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. ( Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013) |
| "Fondaparinux has demonstrated equivalence to enoxaparin in reducing cardiovascular events, but with a lower rate of bleeding in patients using fondaparinux." | 1.38 | Cost-effectiveness of fondaparinux in patients with acute coronary syndrome without ST-segment elevation. ( Machado, M; Olimpio, A; Pepe, C; Ramos, R, 2012) |
| "We report a case of bilateral pulmonary embolism in a patient of 50 years." | 1.37 | [Pulmonary embolism mimicking acute anterior myocardial infarction: diagnostic trap]. ( Bodian, M; Diack, B; Diao, M; Hakim, R; Kagambèga, LJ; Kane, A; Kane, M; Mbaye, A; Ndiaye, MB; Pessinaba, S; Sow, DD; Yaméogo, NV, 2011) |
| " Enoxaparin was dosed as 1 mg/kg regardless of body weight without maximum." | 1.36 | Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. ( Antman, EM; Aylward, PE; Becker, RC; Califf, RM; Col, JJ; Ducas, J; Ferguson, JJ; Gallo, R; Goodman, SG; Langer, A; Levine, GN; Mahaffey, KW; Spinler, SA; Tonev, ST; White, HD, 2010) |
| "Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH." | 1.36 | Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. ( Schiele, F, 2010) |
| "Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways." | 1.35 | Fondaparinux: an overview. ( Banerjee, P; Goyal, D; Lip, GY; Nadar, SK; Shantsila, E, 2009) |
| "To evaluate how enoxaparin is dosed in contemporary clinical practice as a function of patients' total body weight (TBW) and body mass index (BMI), and to determine any association between dose and major bleeding." | 1.35 | Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. ( Alexander, KP; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT; Spinler, SA, 2009) |
| "Important CKD disagreements occur in approximately 20% of acute coronary syndrome patients, affecting dosing adjustments in those already susceptible to bleeding." | 1.35 | Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. ( Alexander, KP; Chen, AY; Gibler, WB; Harrington, RA; Melloni, C; Newby, LK; Ohman, EM; Peterson, ED; Roe, MT; Spinler, SA; Szczech, LA, 2008) |
| " One major adverse clinical event (0." | 1.34 | Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. ( Davis, KE; Denardo, SJ; Tcheng, JE, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 49 (50.00) | 29.6817 |
| 2010's | 42 (42.86) | 24.3611 |
| 2020's | 7 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, CY | 1 |
| Xia, HY | 1 |
| Li, XQ | 1 |
| Jin, LJ | 1 |
| Lu, CL | 1 |
| Ni, RY | 1 |
| Yang, JG | 1 |
| Hu, DY | 1 |
| Guo, JX | 1 |
| Yan, HB | 1 |
| Song, L | 1 |
| Liu, R | 1 |
| Zhao, HJ | 1 |
| Wang, SP | 1 |
| Chi, YP | 1 |
| Zheng, B | 1 |
| Li, WZ | 1 |
| Liu, C | 2 |
| Zhou, P | 1 |
| Latacz, P | 1 |
| Rostoff, P | 1 |
| Wyderka, R | 1 |
| Rudnik, A | 1 |
| Kondys, M | 2 |
| Marut, A | 1 |
| Buszman, P | 2 |
| Piwowarska, W | 1 |
| Camporese, G | 1 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| Zhou, S | 2 |
| Xiao, Y | 2 |
| Zhou, C | 1 |
| Zheng, Z | 1 |
| Jiang, W | 1 |
| Shen, Q | 1 |
| Zhu, C | 1 |
| Pan, H | 1 |
| Zeng, G | 1 |
| Ge, L | 1 |
| Zhang, Y | 2 |
| Ouyang, Z | 1 |
| Fu, G | 1 |
| Pan, G | 1 |
| Chen, F | 1 |
| Huang, L | 1 |
| Liu, Q | 2 |
| Weerasaksanti, A | 1 |
| Siwamogsatham, S | 1 |
| Kunlamas, Y | 1 |
| Bunditanukul, K | 1 |
| Huang, X | 1 |
| Chen, S | 1 |
| Redfors, B | 1 |
| Souza, CF | 1 |
| Mehran, R | 8 |
| Bansilal, S | 1 |
| Kirtane, AJ | 1 |
| Brener, SJ | 2 |
| Feite, F | 1 |
| Dangas, GD | 1 |
| Ben-Yehuda, O | 1 |
| Stone, GW | 9 |
| Rosenthal, N | 1 |
| Xiao, Z | 1 |
| Kartashov, A | 1 |
| Levorsen, A | 1 |
| Shah, BR | 1 |
| Meenpidiyil, SS | 1 |
| Azeez, S | 1 |
| Kumar, VP | 1 |
| Suresh, D | 1 |
| Kalathathoduuill, S | 1 |
| Thandupara, S | 1 |
| Puthukudi, MH | 1 |
| Tang, L | 1 |
| Hu, X | 1 |
| Fang, Z | 1 |
| Almendro-Delia, M | 1 |
| Izquierdo-Bajo, Á | 1 |
| Madrona-Jiménez, L | 1 |
| Blanco-Ponce, E | 1 |
| Seoane-García, T | 1 |
| García-Del Río, M | 1 |
| Carmona-Carmona, J | 1 |
| Arboleda Sánchez, JA | 1 |
| Rodríguez Yáñez, JC | 1 |
| Soto Blanco, JM | 1 |
| Fernández García, I | 1 |
| Castillo Caballero, JA | 1 |
| Hidalgo-Urbano, RJ | 1 |
| García-Rubira, JC | 1 |
| Bundhun, PK | 1 |
| Shaik, M | 1 |
| Yuan, J | 1 |
| Echavarría-Pinto, M | 1 |
| Lopes, R | 1 |
| Gorgadze, T | 1 |
| Gonzalo, N | 1 |
| Hernández, R | 1 |
| Jiménez-Quevedo, P | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Nuñez-Gil, IJ | 1 |
| Ibañez, B | 1 |
| Fernández, C | 1 |
| Fernandez-Ortiz, A | 1 |
| García, E | 1 |
| Macaya, C | 1 |
| Escaned, J | 1 |
| Vavalle, JP | 1 |
| Clare, R | 1 |
| Chiswell, K | 1 |
| Rao, SV | 2 |
| Petersen, JL | 2 |
| Kleiman, NS | 6 |
| Mahaffey, KW | 14 |
| Wang, TY | 1 |
| Clemens, A | 1 |
| Fraessdorf, M | 1 |
| Friedman, J | 1 |
| Singh, D | 1 |
| Gupta, K | 1 |
| Vacek, JL | 1 |
| Jinatongthai, P | 1 |
| Khaisombut, N | 1 |
| Likittanasombat, K | 1 |
| Chaiyakunapruk, N | 2 |
| Watcharathanakij, S | 1 |
| Nathisuwan, S | 2 |
| Huber, K | 2 |
| Bates, ER | 1 |
| Valgimigli, M | 2 |
| Wallentin, L | 4 |
| Kristensen, SD | 1 |
| Anderson, JL | 1 |
| Lopez Sendon, JL | 1 |
| Tubaro, M | 1 |
| Granger, CB | 6 |
| Bode, C | 1 |
| Ohman, EM | 8 |
| Steg, PG | 4 |
| Permsuwan, U | 1 |
| Sukonthasarn, A | 1 |
| Geisler, T | 1 |
| Droppa, M | 1 |
| Gawaz, M | 1 |
| Steinhubl, SR | 2 |
| Bertrand, ME | 5 |
| Lincoff, AM | 3 |
| Cequier, AR | 1 |
| Desmet, W | 2 |
| Rasmussen, LH | 2 |
| Hoekstra, JW | 4 |
| Bernstein, D | 1 |
| Deliargyris, EN | 1 |
| Mayer, M | 2 |
| Ross Terres, JA | 1 |
| Lozano-Ortega, G | 2 |
| Kendall, R | 1 |
| Sculpher, MJ | 2 |
| Wilczynski, M | 1 |
| Wybraniec, MT | 1 |
| Milewski, K | 1 |
| Sanak, M | 1 |
| Wita, K | 1 |
| Buldak, Ł | 1 |
| Bochenek, A | 1 |
| Soeiro, AM | 1 |
| Silva, PG | 1 |
| Roque, EA | 1 |
| Bossa, AS | 1 |
| César, MC | 1 |
| Simões, SA | 1 |
| Okada, MY | 1 |
| Leal, TC | 1 |
| Pedroti, FC | 1 |
| Oliveira, MT | 1 |
| Lopes, RD | 2 |
| Alexander, KP | 5 |
| Marcucci, G | 1 |
| White, HD | 12 |
| Spinler, S | 1 |
| Col, J | 1 |
| Aylward, PE | 7 |
| Califf, RM | 10 |
| Leung, S | 1 |
| Gallup, D | 1 |
| Cohen, M | 7 |
| Antman, EM | 8 |
| Goodman, SG | 7 |
| Harrington, RA | 3 |
| Langer, A | 5 |
| Aylward, P | 1 |
| Ferguson, JJ | 8 |
| Galvani, M | 1 |
| De Vita, M | 1 |
| Bassand, JP | 7 |
| Hamm, C | 1 |
| Budaj, A | 6 |
| Eikelboom, JW | 4 |
| Mehta, SR | 7 |
| Afzal, R | 6 |
| Chrolavicius, S | 5 |
| Fox, KA | 6 |
| Peters, RJ | 2 |
| Joyner, CD | 4 |
| Yusuf, S | 6 |
| Colombo, A | 1 |
| McLaurin, BT | 1 |
| Cox, DA | 1 |
| Pocock, SJ | 1 |
| Ware, JA | 1 |
| Manoukian, SV | 5 |
| Lansky, AJ | 2 |
| Moses, JW | 1 |
| Yan, AT | 1 |
| Yan, RT | 1 |
| Huynh, T | 1 |
| DeYoung, P | 1 |
| Weeks, A | 1 |
| Fitchett, DH | 1 |
| Boden, WE | 2 |
| Flather, M | 3 |
| Avezum, A | 1 |
| Piegas, LS | 1 |
| Faxon, DP | 2 |
| Widimsky, P | 2 |
| Rupprecht, HJ | 2 |
| Jolly, S | 1 |
| Tonev, ST | 1 |
| Spinler, SA | 3 |
| Levine, GN | 2 |
| Gallo, R | 1 |
| Ducas, J | 1 |
| Becker, RC | 2 |
| Col, JJ | 3 |
| Kruse, MW | 1 |
| Lee, JJ | 1 |
| Heer, T | 1 |
| Juenger, C | 1 |
| Gitt, AK | 1 |
| Bauer, T | 1 |
| Towae, F | 1 |
| Zahn, R | 1 |
| Senges, J | 1 |
| Zeymer, U | 2 |
| Bhatt, DL | 1 |
| Franzosi, MG | 1 |
| Martin, JL | 2 |
| Fry, ET | 1 |
| Martin, T | 1 |
| Atherley, TH | 1 |
| Martin, SS | 1 |
| Slepian, MJ | 1 |
| Karthikeyan, G | 1 |
| Feit, F | 4 |
| Pollack, CV | 6 |
| Hoekstra, J | 1 |
| Gersh, BJ | 3 |
| Sambrook, J | 1 |
| Palmer, S | 1 |
| Ormanidhi, O | 1 |
| Bakhai, A | 1 |
| Weintraub, W | 1 |
| Cristea, E | 1 |
| Parise, H | 1 |
| Hamon, M | 2 |
| Mitrovska, S | 1 |
| Jovanova, S | 1 |
| Chan, MY | 1 |
| Sun, LJ | 1 |
| Pieper, KS | 6 |
| Roe, MT | 4 |
| Ou, FS | 1 |
| Gibler, WB | 2 |
| Peterson, ED | 2 |
| Hollander, JE | 2 |
| Gibson, CM | 3 |
| Nadar, SK | 1 |
| Goyal, D | 1 |
| Shantsila, E | 1 |
| Banerjee, P | 1 |
| Lip, GY | 1 |
| Roffi, M | 2 |
| Eberli, FR | 1 |
| Cequier, A | 1 |
| Lincoff, MA | 1 |
| Mann, T | 1 |
| Drouet, L | 1 |
| Bal dit Sollier, C | 1 |
| Martin, J | 1 |
| Jolly, SS | 1 |
| Valentin, V | 1 |
| Miller, CD | 2 |
| Blomkalns, AL | 1 |
| Brogan, GX | 1 |
| Diercks, DB | 1 |
| Peacock, WF | 1 |
| Eikelboom, J | 1 |
| Peters, R | 1 |
| Mehta, S | 1 |
| Anderson, JA | 1 |
| Hirsh, J | 1 |
| Johnston, M | 1 |
| Walters, DL | 1 |
| Ray, MJ | 1 |
| Wood, P | 1 |
| Perrin, EJ | 1 |
| Bett, JH | 1 |
| Aroney, CN | 1 |
| Damman, P | 1 |
| Hirsch, A | 1 |
| Windhausen, F | 1 |
| Tijssen, JG | 1 |
| de Winter, RJ | 1 |
| Schiele, F | 2 |
| Meneveau, N | 1 |
| Seronde, MF | 1 |
| Descotes-Genon, V | 1 |
| Dutheil, J | 1 |
| Chopard, R | 1 |
| Ecarnot, F | 1 |
| Deal, EN | 1 |
| Hollands, JM | 1 |
| Lan, L | 1 |
| Danchin, N | 1 |
| Aïssaoui, N | 1 |
| Bhattacharya, R | 1 |
| Pani, A | 1 |
| Dutta, D | 1 |
| Basak, S | 1 |
| Gangopadhyay, S | 1 |
| Das Baksi, S | 1 |
| Sarkar, RN | 1 |
| Zhang, M | 1 |
| Tsiatis, AA | 1 |
| Davidian, M | 1 |
| Yang, H | 1 |
| Marian, AJ | 1 |
| Furman, MI | 1 |
| Michael Lincoff, A | 1 |
| Hazen, SL | 1 |
| Reist, CJ | 1 |
| Gomes, M | 1 |
| Ramacciotti, E | 1 |
| Litinas, E | 1 |
| Fareed, J | 1 |
| Slepian, M | 1 |
| Yaméogo, NV | 1 |
| Mbaye, A | 1 |
| Kagambèga, LJ | 1 |
| Diack, B | 1 |
| Pessinaba, S | 1 |
| Hakim, R | 1 |
| Ndiaye, MB | 1 |
| Bodian, M | 1 |
| Diao, M | 1 |
| Sow, DD | 1 |
| Kane, M | 1 |
| Kane, A | 1 |
| Lokhnygina, Y | 2 |
| Hochman, JS | 1 |
| Iqbal, Z | 1 |
| Martí, V | 1 |
| García-Picart, J | 1 |
| Carballeira, L | 1 |
| Carballo, S | 1 |
| Carballo, D | 1 |
| Keller, PF | 2 |
| Baber, U | 1 |
| Ng, FH | 2 |
| Tunggal, P | 1 |
| Chu, WM | 2 |
| Lam, KF | 2 |
| Li, A | 1 |
| Chan, K | 1 |
| Lau, YK | 2 |
| Kng, C | 1 |
| Keung, KK | 1 |
| Kwan, A | 1 |
| Wong, BC | 2 |
| Silvain, J | 2 |
| Beygui, F | 1 |
| Barthélémy, O | 1 |
| Pollack, C | 1 |
| Goldstein, P | 1 |
| Cayla, G | 1 |
| Collet, JP | 1 |
| Vicaut, E | 1 |
| Montalescot, G | 2 |
| James, S | 1 |
| Kossovsky, M | 1 |
| Mach, F | 1 |
| Gaspoz, JM | 1 |
| Pepe, C | 1 |
| Machado, M | 1 |
| Olimpio, A | 1 |
| Ramos, R | 1 |
| Murphy, SA | 1 |
| Morrow, DA | 2 |
| Van de Werf, F | 1 |
| Menown, IB | 1 |
| McCabe, CH | 1 |
| Braunwald, E | 1 |
| Eriksson, BI | 1 |
| Dahl, OE | 1 |
| Rosencher, N | 1 |
| Kurth, AA | 1 |
| van Dijk, CN | 1 |
| Frostick, SP | 1 |
| Kälebo, P | 1 |
| Christiansen, AV | 1 |
| Hantel, S | 1 |
| Hettiarachchi, R | 1 |
| Schnee, J | 1 |
| Büller, HR | 1 |
| Denardo, SJ | 1 |
| Davis, KE | 1 |
| Tcheng, JE | 1 |
| Tricoci, P | 1 |
| Berdan, LG | 1 |
| Gulba, DC | 1 |
| Newby, LK | 2 |
| Richard-Lordereau, I | 1 |
| Cadroy, Y | 1 |
| Normand, SL | 1 |
| Yeh, RW | 1 |
| Wiviott, SD | 1 |
| Giugliano, RP | 1 |
| Shui, A | 1 |
| Qin, J | 1 |
| Scirica, B | 1 |
| Bradner, JE | 1 |
| Jang, IK | 1 |
| Wong, SY | 1 |
| Chang, CM | 1 |
| Yang, Q | 1 |
| Reist, C | 1 |
| Chew, DP | 3 |
| Huang, Z | 2 |
| White, H | 1 |
| Aylward, PG | 1 |
| Kwa, AT | 1 |
| Rogers, JH | 1 |
| Melloni, C | 1 |
| Chen, AY | 1 |
| Szczech, LA | 1 |
| Ebrahimi, R | 1 |
| Attubato, MJ | 1 |
| Bertrand, M | 1 |
| Pocock, S | 1 |
| Ware, J | 1 |
| Barantke, M | 1 |
| Bonnemeier, H | 1 |
| Eggers, KM | 1 |
| Lagerqvist, B | 1 |
| Oldgren, J | 1 |
| Venge, P | 1 |
| Lindahl, B | 1 |
| Goldman, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial[NCT03363035] | Phase 4 | 2,055 participants (Actual) | Interventional | 2018-01-15 | Completed | ||
| The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158] | Phase 3 | 13,800 participants | Interventional | 2003-08-31 | Completed | ||
| A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784] | Phase 3 | 8,000 participants | Interventional | 2001-08-31 | Completed | ||
| A Phase I, Pharmacokinetic and Tolerability Study of Intravenous Unfractionated Heparin After Subcutaneous Enoxaparin 1mg/kg Bid Repeated Administration in Healthy Subjects[NCT00622115] | Phase 1 | 72 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes[NCT00139815] | Phase 3 | 20,078 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Influence of the Compression Method After Transradial Catheterization in Radial Artery[NCT02697526] | 274 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction[NCT00683111] | Phase 4 | 500 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| Beijing Tiantan Hospital,Capital Medical University.[NCT02317445] | 472 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for dalteparin and Acute Coronary Syndrome
| Article | Year |
|---|---|
Update on the clinical use of the low-molecular-weight heparin, parnaparin.
Topics: Acute Coronary Syndrome; Anticoagulants; Arterial Occlusive Diseases; Cardiovascular Diseases; Drug | 2009 |
Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Chi-Square Distribution; Enoxaparin; Female; Fondapar | 2017 |
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution | 2013 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogr | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, | 2014 |
Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; American Heart Association; Angina, Unstable; Anticoagulants; Clinical Tria | 2017 |
Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Emerg | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopido | 2010 |
Use of low-molecular-weight heparins during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Cardiac Catheteriz | 2011 |
Enoxaparin: a pharmacologic and clinical review.
Topics: Acute Coronary Syndrome; Anticoagulants; Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecula | 2011 |
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Hemorrhage; Hep | 2012 |
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
Topics: Acute Coronary Syndrome; Antithrombins; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; | 2007 |
Efficacy and safety of fondaparinux in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxa | 2007 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Factor Xa inactivation in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fondapa | 2008 |
Dalteparin as the primary low-molecular-weight heparin on a hospital formulary.
Topics: Acute Coronary Syndrome; Anticoagulants; Dalteparin; Fibrinolytic Agents; Formularies, Hospital as T | 2009 |
41 trials available for dalteparin and Acute Coronary Syndrome
| Article | Year |
|---|---|
[Efficacy comparison with low and high dose nadroparin for patients with acute coronary syndrome underwent percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Female; Humans; Male; | 2008 |
Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Female; Fibrinolytic Agents; Fondaparinux; Humans; Ma | 2011 |
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Male; Platelet Aggre | 2023 |
Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE.
Topics: Acute Coronary Syndrome; Anticoagulants; Asian People; Dose-Response Relationship, Drug; Enoxaparin; | 2022 |
Use of the CRUSADE bleeding risk score in the prediction of major bleeding for patients with acute coronary syndrome receiving enoxaparin in Thailand.
Topics: Acute Coronary Syndrome; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle A | 2014 |
Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Coronary Artery Bypass; Drug Therapy, | 2016 |
Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Enoxaparin; Eptifibatide; Female; Fibrinol | 2016 |
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anticoagulants; Coronary Angiography; Cross-Over Studies | 2008 |
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Antithrombins; Dose-Response Relationship, Drug; | 2008 |
[The ACUITY trial: one-year results].
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Hirudins; Humans; Peptide Fragments; Platelet G | 2008 |
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Humans; | 2009 |
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Tria
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula | 2008 |
Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Electrocardiography, Ambulatory; Enoxaparin; Eptifiba | 2008 |
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Double-Blind Method; | 2008 |
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Polysaccharid | 2009 |
The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Factor Xa | 2009 |
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Aged; Aging; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Arter | 2009 |
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Cost-Benefit Analysis; Electrocardiography; Enoxaparin; Fac | 2009 |
Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary | 2009 |
Low-molecular weight heparin enoxaparin in the treatment of acute coronary syndromes without ST segment elevation.
Topics: Acute Coronary Syndrome; Anticoagulants; Electrocardiography; Enoxaparin; Heparin; Humans; Survival | 2009 |
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; | 2008 |
Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula | 2009 |
Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
Topics: Acute Coronary Syndrome; Adult; Blood Coagulation; Enoxaparin; Female; Heparin; Humans; Male; Middle | 2009 |
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) tria
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Fondap | 2009 |
Safety and efficacy of bivalirudin in high-risk patients admitted through the emergency department.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Chi-Square Distribution; Comorbidity; Emergency Servi | 2009 |
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; | 2010 |
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; | 2010 |
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; | 2010 |
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; | 2010 |
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Blood Coagulation; Dose-Response Relationship, Drug; | 2010 |
High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Biomarkers; Blood Coagulation F | 2010 |
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary
Topics: Abciximab; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; An | 2010 |
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Enoxaparin; Fema | 2010 |
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administ | 2010 |
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Coagulation Factor Inhibitors; Blood Platelets; CD4 | 2011 |
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cross-Over Studies; Enoxaparin; Female; Hemorrhage; H | 2011 |
Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Chi-Square Distribution; Clopidogrel; Dou | 2012 |
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Clin | 2007 |
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Comorbidity; Enoxaparin; Female; Heparin; Humans; Inc | 2007 |
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cause of Death; Coronary Angiography; Dose-Respons | 2008 |
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Electrocardiography; Enoxaparin; | 2008 |
Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Cardiac Cath | 2008 |
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgen
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heart C | 2008 |
Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Dalteparin; Echocardiography; Female; Fibrinolytic Agents | 2008 |
40 other studies available for dalteparin and Acute Coronary Syndrome
| Article | Year |
|---|---|
[Effectiveness and safety of nadroparin in acute coronary syndrome].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Anticoagulants; Factor Xa Inhibitors; Humans; Nadropa | 2007 |
[Massive pulmonary embolism mimicking ST-elevation acute coronary syndrome successfully treated with hybrid therapy in a trauma patient receiving nadroparin: diagnostic and therapeutic dilemmas].
Topics: Acute Coronary Syndrome; Angiocardiography; Angioplasty, Balloon; Diagnosis, Differential; Drug Ther | 2007 |
Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Retrospective Studies; Thai | 2023 |
Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triag
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Creatine Kinase, MB Form; Enoxaparin; | 2020 |
Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Comorbidity; E | 2021 |
Enoxaparin induced reactive thrombocytosis: a rare adverse drug reaction.
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Female; Humans; Injections, Subcutaneous; Middl | 2020 |
Fondaparinux versus enoxaparin in the contemporary management of non-ST-elevation acute coronary syndromes. Insights from a multicenter registry.
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Fondaparinux; Humans; Polysaccharides; Prospect | 2021 |
Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus.
Topics: Acute Coronary Syndrome; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopi | 2013 |
Prognostic significance of bleeding location and severity among patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Blood Loss, Surgical; Coronary Artery Bypass; Enoxapa | 2013 |
Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand.
Topics: Acute Coronary Syndrome; Aged; Costs and Cost Analysis; Enoxaparin; Female; Fondaparinux; Humans; Ma | 2015 |
Elucidating the use of enoxaparin in non-ST-elevation acute coronary syndromes (NSTE-ACS).
Topics: Acute Coronary Syndrome; Administration, Intravenous; Anticoagulants; Enoxaparin; Humans; Injections | 2016 |
Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
Topics: Acute Coronary Syndrome; Anticoagulants; Canada; Cost-Benefit Analysis; Decision Support Techniques; | 2015 |
Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Brazil; Enoxaparin; Female; Fondaparinux; Hemorrhage; | 2016 |
Guidelines for anticoagulant use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Europe; Humans; Practice Guidelines as Topic | 2008 |
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Body Mass Index; Comorbidity; Data | 2010 |
Bias in AJHP supplements.
Topics: Acute Coronary Syndrome; Bias; Conflict of Interest; Drug Industry; Enoxaparin; Fibrinolytic Agents; | 2008 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru | 2009 |
The pain and the gain of treating patients with acute coronary syndromes-can the two be separated?
Topics: Acute Coronary Syndrome; Anticoagulants; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Myocardial Is | 2009 |
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
Topics: Acute Coronary Syndrome; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fond | 2009 |
Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticoagulants; Body Weight; Cohort Studies; Enoxap | 2009 |
Fondaparinux: an overview.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Drug Interactions; Enoxapar | 2009 |
Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Heparin; Humans; Ma | 2010 |
Contraindicated medication use in dialysis patients.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Contraindications; Drug Labeling; Enoxapari | 2010 |
Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.
Topics: Acute Coronary Syndrome; Anticoagulants; Catheterization; Enoxaparin; Fondaparinux; Hirudins; Humans | 2010 |
Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.
Topics: Acute Coronary Syndrome; Algorithms; Computer Simulation; Endpoint Determination; Enoxaparin; Hemorr | 2011 |
[Concerns on generic enoxaparin use in acute coronary syndrome].
Topics: Acute Coronary Syndrome; Anticoagulants; Clinical Trials as Topic; Drug Approval; Drugs, Generic; En | 2010 |
[Pulmonary embolism mimicking acute anterior myocardial infarction: diagnostic trap].
Topics: Acenocoumarol; Acute Coronary Syndrome; Anterior Wall Myocardial Infarction; Anticoagulants; Coronar | 2011 |
[Acute coronary syndrome due to distal embolization of a thrombus located in the left main coronary artery].
Topics: Acute Coronary Syndrome; Angina Pectoris; Angiography; Anticoagulants; Coronary Thrombosis; Electroc | 2011 |
[Specificities of diabetes in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogr | 2011 |
Acute coronary syndromes: Antithrombotics in ACS--moving beyond unfractionated heparin.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Enoxaparin; Fibrinolytic Agents; Heparin; Hi | 2011 |
Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Heparin; Humans | 2012 |
Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Costs and Cost Analysis; Drug Costs; Enoxaparin; Fact | 2012 |
Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Thrombosis; Enoxap | 2012 |
Cost-effectiveness of fondaparinux in patients with acute coronary syndrome without ST-segment elevation.
Topics: Acute Coronary Syndrome; Anticoagulants; Brazil; Cost-Benefit Analysis; Enoxaparin; Female; Fondapar | 2012 |
Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atherectomy, Coronary; Clopidogrel; Coronary | 2007 |
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Coronary Angiography; Enoxaparin; Female; Fibrinol | 2007 |
Evaluating the optimal timing of angiography: landmark or off the mark?
Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Coronary Angiography; Enoxaparin; Female; Fibrinol | 2007 |
Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Creatinine; Enoxaparin; Female; Fibrinolytic Agents; Glo | 2008 |
Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Coronary Artery Bypass; Enoxaparin; Forecasting; Huma | 2008 |